Hikma welcomes FDA approval of Guardant360® Liquid CDx

▤ Summary

Hikma highlights FDA approval of Guardant360 Liquid CDx, a liquid biopsy test developed by Guardant Health for advanced cancer care. The test uses a blood draw to profile tumor DNA and epigenetic signals, giving clinicians a less invasive alternative to tissue-based biomarker testing. The approval transfers seven companion diagnostic indications from the earlier Guardant360 CDx to the new Liquid CDx version. Hikma also points to its exclusive MENA commercialization agreement with Guardant Health, which supports broader regional adoption of precision oncology diagnostics.

▦ Linked Companies